Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganciclovir for Prevention of CMV Reactivation in Acute Lung Injury
NCT01335932Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2011
- Primary completion
- Jun 2016
- Countries
- 1
- Sponsor
- Fred Hutchinson Cancer Center
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Drugs
- ganciclovir
- Conditions
- cytomegalovirus infection (CMV)
01
Overview
Phase 2, randomised, double-blind trial of ganciclovir in cytomegalovirus infection (CMV), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Serum Interleukin-6 at Day 14. Started Mar 2011; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
CMV seropositive adults (>=18 years) with acute lung injury/ARDS requiring mechanical ventilation, meeting criteria for severe sepsis or trauma (ISS > 15), and not immunocompromised.
04
Endpoints
Primary
Serum Interleukin-6
Beyond the preview
Go deeper on NCT01335932.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01335932.